An interventional study of Collect blood sample in Carbapenem-resistant Enterobacteriaceae, sponsored by Phramongkutklao College of Medicine and Hospital. Recruiting at 1 site in Thailand. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2023-09-22.
Sponsored by Phramongkutklao College of Medicine and Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Sepsis with a site in Thailand — 7 open to participants now, 8 under way, none of them phase 3. Sepsis · Thailand.
Among the 38 studies in Sepsis with a site in Thailand, this one is the 21st largest by planned enrollment of the 27 interventional ones that give a count, is the only one that started in 2023, is one of 15 with no phase, and was the 28th registered.
2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.
Browse Sepsis studies →7 of the 38 studies in Sepsis with a site in Thailand are open now. Recruiting first, the newest first:
KK Women's and Children's Hospital · Sites in Thailand, China, Hong Kong and 6 more countries
Ages up to 18
Siriraj Hospital · Sites in Thailand
Ages 18+
National University of Singapore · Sites in Thailand, Australia, China and 9 more countries
Ages 18+
Navamindradhiraj University · Sites in Thailand
Ages 18+
Mahidol University · Sites in Thailand
Ages 19–90
A study can be open while its sites in Thailand have not opened yet or have stopped. Only those recruiting at a site in Thailand →
Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 72 is below the median of 102 across 1,169 interventional studies indexed under Sepsis.
Median enrollment 197 across the 27 interventional studies, 900 across the 10 observational. Of the 27 that completed or were terminated, 5 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 38 have an industry lead sponsor. The 10 most frequent:
Phramongkutklao College of Medicine and Hospital is the lead sponsor of 37 studies on the registry; 7 are open to participants now.
Phramongkutklao College of Medicine and Hospital has 2 studies filed under Sepsis — fewer than ten, so there is no comparison to draw.
1 of the studies in Sepsis with a site in Thailand that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07438301Mahidol UniversitySeptic Shock Hemodynamic Respond to Volume Resuscitation Versus Vasopressor Administration | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 38 studies in Sepsis with a site in Thailand, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Carbapenem-resistant Enterobacteriaceae (CRE) are an urgent global public health problem. Patients who were infected caused by CRE bloodstream infection were high mortality up to 40%. The National Antimicrobial Resistance Surveillance Center, Thailand (NARST) reported CRE increased from 1.1% to 17.9%. For carbapenemase producing CRE in Thailand was reported blaNDM 47.33%, blaOXA-48 43.33% and blaNDM+blaOXA-48 6.67%.
Tigecycline (TGC) was a glycylcyclines antibiotics. High dose tigecycline (HD-TGC) loading dose 200 mg then TGC 100 mg q 12 h via intravenous improve clinical cure in critically ill patients and reduce mortality in carbapenem resistance Klebsiella pneumoniae bloodstream infection compared with standard dose therapy. TGC has susceptibility to CR-KP 79.6% and has an activity to blaNDM, blaKPC and blaOXA-48 carbapenemase producing CRE. However, TGC has clearance (CL) 0.2-0.3 L/h/kg, and high volume of distribution (vd) 2.8-13 L/kg resulted in low levels of TGC in plasma. Moreover, the pharmacokinetics of TGC in critically ill was limited and inconsistent with the previous study. Now pharmacokinetics-pharmacodynamics index (PK/PD index) of TGC for CRE bloodstream infection was not reported. This study aims to study the population pharmacokinetic and PK-PD index of TGC in patients who were CRE bloodstream infection to increase the success rate of treatment.
Carbapenem-resistant Enterobacteriaceae (CRE) are an urgent global public health problem. Patients who were infected caused by CRE bloodstream infection were high mortality up to 40%. The National Antimicrobial Resistance Surveillance Center, Thailand (NARST) reported the carbapenem resistance Klebsiella pneumoniae (CR-KP) prevalence increased from 1.1% in 2000 to 17.9% in 2021 and the carbapenem resistance Escherichia coli was increased from 0.6% in 2000 to 5% in 2021. For carbapenemase producing CRE in Thailand was reported blaNDM 47.33%, blaOXA-48 43.33%, and blaNDM+blaOXA-48 6.67%. Ceftazidime-avibactam was first-line of treatment for CRE bloodstream infection recommended by Infectious Disease Society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections but ceftazidime-avibactam was limited activity to blaNDM carbapenemase producing CRE.
Tigecycline (TGC) was a glycylcyclines antibiotics. TGC was approved for U.S.FDA for complicated intra-abdominal infection, complicated skin and skin structure infection and community acquired pneumonia with loading dose TGC 100 mg then TGC 50 mg q 12 h via intravenous. High dose tigecycline (HD-TGC) loading dose 200 mg then TGC 100 mg q 12 h improve clinical cure in critically ill patients and reduce mortality in CR-KP bloodstream infection compared with standard dose therapy. TGC has susceptibility to CR-KP 79.6% and has an activity to blaNDM, blaKPC and blaOXA-48 carbapenemase producing CRE. However, TGC has clearance (CL) 0.2-0.3 L/h/kg, and high volume of distribution (vd) 2.8-13 L/kg resulted in low levels of TGC in plasma. Moreover, the pharmacokinetics of TGC in critically ill was limited and inconsistent with the previous study. Now pharmacokinetics-pharmacodynamics index (PK/PD index) of TGC for CRE bloodstream infection was not reported. This study aims to study the population pharmacokinetic and PK-PD index of TGC in patients who were CRE bloodstream infection to increase the success rate of treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients who were infected caused by CRE bloodstream infection and were treated with tigecycline. Blood samples were collected.
Other: Collect blood sample
Collect blood samples at different time points: after tigecycline administration 1 h, 2-4 h, 4-6 h, 6-11.5 h and 30 minutes before next dose
rate constant for tigecycline distribution from the central to the peripheral compartment
Population pharmacokinetic parameter outcome of tigecycline
Time frame: up to 6 months
rate constant for tigecycline distribution from the peripheral to central the compartment
Population pharmacokinetic parameter outcome of tigecycline
Time frame: up to 6 months
elimination rate constant
Population pharmacokinetic parameter of tigecycline
Time frame: up to 6 months
intercompartmental clearance
Population pharmacokinetic parameter outcome of tigecycline
Time frame: up to 6 months
total clearance
Population pharmacokinetic parameter outcome of tigecycline
Time frame: up to 6 months
volume of central compartment
Population pharmacokinetic parameter outcome of tigecycline
Time frame: up to 6 months
volume distribution of peripheral compartment
Population pharmacokinetic parameter outcome of tigecycline
Time frame: up to 6 months
steady state volume distribution
Population pharmacokinetic parameter outcome of tigecycline
Time frame: up to 6 months
Area under the plasma concentration versus time curve (AUC)
Population pharmacokinetic parameter outcome of tigecycline
Time frame: up to 6 months
Peak Plasma Concentration (Cmax)
Population pharmacokinetic parameter outcome of tigecycline
Time frame: up to 6 months
PK/PD index for CRE bloodstream infection
pharmacokinetics-pharmacodynamics parameter of tigecycline for CRE bloodstream infection
Time frame: up to 6 months
Rate of mortality
Alive or death
Time frame: 7,14 and 28 days
Number of Participants with the clinical outcome
Clinical cure or clinical failure Clinical cure was defined as the resolution or improvement of all signs and symptoms present at study entry Clinical failure was defined as any one or more following circumstances: persistent or worsened signs and symptoms, a new clinical findings consistent with the progression of infection.
Time frame: 14 days
Number of Participants with the microbiological outcome
Eradicated or persistent evaluated by culture of bloodstream
Time frame: 7 days
Genotype classification of carbapenemase producing CRE
Time frame: up to 6 months
Start is estimated for Sep 2023; primary completion for May 2025, 20 months later.
Of 303 non-industry interventional studies with no phase under Sepsis, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's planned 20 months is below that.
Counting every sponsor, half of 326 studies reached it within 22 months; a quarter within 11 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Phramongkutklao College of Medicine and Hospital